References
1. Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. Lancet 2022;399(10343):2310-2324.
2. Goh LPW, Chong ETJ, Lee PC. Prevalence of alpha-thalassemia in Southeast Asia (2010-2020): A meta-analysis involving 83,674 subjects. Int J Environ Res Public Health 2020;17(20).
3. Piel FB, Weatherall DJ. The alpha-thalassemias. N Engl J Med 2014;371(20):1908-1916.
4. Singer ST, Kim HY, Olivieri NF, Kwiatkowski JL, Coates TD, Carson S, et al. Hemoglobin h-constant spring in north america: An alpha-thalassemia with frequent complications. Am J Hematol 2009;84(11):759-761.
5. Wong P, Fuller PJ, Gillespie MT, Milat F. Bone disease in thalassemia: A molecular and clinical overview. Endocr Rev 2016;37(4):320-346.
6. Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N, et al. Thalassemia-associated osteoporosis: A systematic review on treatment and brief overview of the disease. Osteoporos Int 2016;27(12):3409-3425.
7. Farr JN, Melton LJ, 3rd, Achenbach SJ, Atkinson EJ, Khosla S, Amin S. Fracture incidence and characteristics in young adults aged 18 to 49 years: A population-based study. J Bone Miner Res 2017;32(12):2347-2354.
8. Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, et al. Prevalence of fractures among the thalassemia syndromes in north america. Bone 2006;38(4):571-575.
9. Charoenngam N, Rittiphairoj T, Ponvilawan B. Fracture prevalence in thalassemia: A systematic review and meta-analysis. Arch Osteoporos 2021;16(1):171.
10. Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC, et al. Thalassemia bone disease: A 19-year longitudinal analysis. J Bone Miner Res 2014;29(11):2468-2473.
11. Piriyakhuntorn P, Tantiworawit A, Phimphilai M, Srichairatanakool S, Teeyasoontranon W, Rattanathammethee T, et al. Prevalence and risk factors of low bone mineral density and fractures of young thalassemia patients. Blood 2018;132(Suppl 1):3636-3636.
12. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, et al. Bone disease in thalassemia: A frequent and still unresolved problem. J Bone Miner Res 2009;24(3):543-557.
13. Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ. Low bone mineral density in adolescents with beta-thalassemia. Ann N Y Acad Sci 2005;1054(1):462-466.
14. McCormack SE, Cousminer DL, Chesi A, Mitchell JA, Roy SM, Kalkwarf HJ, et al. Association between linear growth and bone accrual in a diverse cohort of children and adolescents. JAMA Pediatr 2017;171(9):e171769.
15. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012;33(5):747-783.
16. Sapunarova K, Goranova-Marinova V, Georgiev P, Deneva T, Tsvetkova S, Grudeva-Popova Z. Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia. Ann Med 2020;52(3-4):94-108.
17. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 2012;44(12):909-913.
18. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, et al. Serum dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009;94(5):725-728.
19. Ahmed SF, Fouda N, Abbas AA. Serum dickkopf-1 level in postmenopausal females: Correlation with bone mineral density and serum biochemical markers. J Osteoporos 2013;2013:460210.
20. Huang Y, Eapen E, Steele S, Grey V. Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 2011;44(10-11):771-778.
21. Choi JS, Park I, Lee SJ, Ju HJ, Lee H, Kim J. Serum procollagen type-I N-terminal propeptide and osteocalcin levels in Korean children and adolescents. Yonsei Med J 2019;60(12):1174-1180.
22. Nakavachara P, Pooliam J, Weerakulwattana L, Kiattisakthavee P, Chaichanwattanakul K, Manorompatarasarn R, et al. A normal reference of bone mineral density (bmd) measured by dual energy x-ray absorptiometry in healthy Thai children and adolescents aged 5-18 years: A new reference for Southeast Asian populations. PLoS One 2014;9(5):e97218.
23. Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: Results of the Bone Mineral Density in Childhood study. J Clin Endocrinol Metab 2011;96(10):3160-3169.
24. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 2019;22(4):453-471.
25. Pirinççioğlu AG, Akpolat V, Köksal O, Haspolat K, Söker M. Bone mineral density in children with beta-thalassemia major in Diyarbakir. Bone 2011;49(4):819-823.
26. Kothimira VK, Kumar A, Richhele LR, Sood N, Gulati A. An evaluation of bone health parameters in regularly transfused beta-thalassemia major patients. J Pediatr Hematol Oncol 2020;42(6):381-385.
27. Nakavachara P, Petchkul J, Jeerawongpanich K, Kiattisakthavee P, Manpayak T, Netsakulnee P, et al. Prevalence of low bone mass among adolescents with nontransfusion-dependent hemoglobin E/beta-thalassemia and its relationship with anemia severity. Pediatr Blood Cancer 2018;65(1).
28. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr 1997;86(4):342-346.
29. Murphy WG. The sex difference in haemoglobin levels in adults - Mechanisms, causes, and consequences. Blood Rev 2014;28(2):41-47.
30. Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S, et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev 2008;6(Suppl 1:)116-122.
31. Tari E, Vörhendi N, Kiss S, Teutsch B, Váradi A, Sisák K, et al. Anaemia is associated with an increased risk of fractures, a systematic review, and meta-analysis. Gerontology 2023;69(1):1-13.
32. Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J Hepatol 2010;2(8):302-310.
33. Aikaterini N, Chrisavgi T, Pavlos F, Nicoletta B, Lucia Carmela C, Cristina Z, et al. Sex-specific transcriptional profiles identified in β-thalassemia patients. Haematologica 2020;106(4):1207-1211.
34. Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: Function, biological mechanisms, and therapeutic opportunities. Signal Transduc Target Ther 2022;7(1):3.
35. Badiee Z, Sepasizang abadi M, Keshavarzi A, Keramati MR, Ayatollahi H, Sadeghian MH, et al. Serum dickkopf-1 and correlation with bone mineral density in patients with beta thalassemia major in North-Eastern of Iran. ssu-ijml 2018;5(3):188-194.
36. Chiarito M, Piacente L, Chaoul N, Pontrelli P, D’Amato G, Grandone A, et al. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome. J Endocrinol Invest 2022;45(6):1255-1263.
37. Xu Y, Gao C, He J, Gu W, Yi C, Chen B, et al. Sclerostin and its associations with bone metabolism markers and sex hormones in healthy community-dwelling elderly individuals and adolescents. Front Cell Dev Biol 2020;8:57.
38. Mödder UIL, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011;26(1):27-34.
39. Khalil R, Antonio L, Laurent MR, David K, Kim NR, Evenepoel P, et al. Early effects of androgen deprivation on bone and mineral homeostasis in adult men: A prospective cohort study. Eur J Endocrinol 2020;183(2):181-189.